T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) – Pipeline Review, H2 2017’, provides in depth analysis on T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Respiratory under development targeting T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects

The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3SBio Inc

BioAtla LLC

Bristol-Myers Squibb Co

KAHR medical Ltd

MedImmune LLC

Mologen AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Overview 7

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Companies Involved in Therapeutics Development 23

3SBio Inc 23

BioAtla LLC 23

Bristol-Myers Squibb Co 23

KAHR medical Ltd 24

MedImmune LLC 25

Mologen AG 25

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Drug Profiles 26

abatacept - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

abatacept biosimilar - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

abatacept biosimilar - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

abatacept biosimilar - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CUE-201 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

KAHR-102 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

KN-019 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

MEDI-5265 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

MGN-1601 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Dormant Products 50

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Discontinued Products 52

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Product Development Milestones 53

Featured News & Press Releases 53

Nov 13, 2017: Bristol-Myers Squibb’s Orencia Rejects For Use Within NHS Scotland 53

Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 53

Jul 26, 2017: Bristol-Myers Squibb’s ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis 59

Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults 59

Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017) 61

Jun 08, 2017: Bristol-Myers Squibb Announces Availability of New ORENCIA (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis 65

Mar 13, 2017: Bristol-Myers Squibb's Orencia Rejects For Use Within NHS Scotland 67

Nov 14, 2016: Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 67

Nov 10, 2016: Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 68

Sep 06, 2016: European Commission Approves Bristol-Myers Squibb’s ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate 72

Jul 25, 2016: CHMP Issues Positive Opinion for ORENCIA (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU 73

Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Orencia 74

Jul 20, 2016: Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA (abatacept) ClickJect, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis 75

Jun 08, 2016: Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016) 76

May 25, 2016: Launch of Orencia SC 125 mg Auto-injector 1 mL for Treatment of Rheumatoid Arthritis 80

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Stage and Route of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by 3SBio Inc, H2 2017 23

Pipeline by BioAtla LLC, H2 2017 23

Pipeline by Bristol-Myers Squibb Co, H2 2017 24

Pipeline by KAHR medical Ltd, H2 2017 25

Pipeline by MedImmune LLC, H2 2017 25

Pipeline by Mologen AG, H2 2017 25

Dormant Products, H2 2017 50

Dormant Products, H2 2017 (Contd..1), H2 2017 51

Discontinued Products, H2 2017 52

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 19

Number of Products by Stage and Routes of Administration, H2 2017 19

Number of Products by Molecule Types, H2 2017 21

Number of Products by Stage and Molecule Types, H2 2017 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports